ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The NIH Chemical Genomics Center (NCGC) has built a comprehensive collection of clinically approved small-molecule drugs that could help jump-start development of treatments for rare and neglected diseases. The NCGC Pharmaceutical Collection (NPC) was created as both a publicly available electronic database and a screening resource. The database, which is described in the April 27 issue of Science Translational Medicine (DOI: 10.1126/scitranslmed.3001862), can be downloaded at tripod.nih.gov/npc. It includes information on 2,750 small-molecule drugs that have been approved for use in the U.S., Canada, Europe, and Japan, as well as data on drugs that are currently being investigated in clinical trials. NCGC hopes to eventually provide information on more than 7,500 drugs that have been tested in humans. So far, NCGC has collected physical samples of 2,400 of the approved drugs, which are provided to researchers through NIH’s Therapeutics for Rare & Neglected Diseases program and the Tox21 initiative, a multiagency effort to use high-throughput screening tools in toxicity testing.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X